Rubicon Research Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Smallcap 250 · Nifty MidSmallcap 400 · Nifty 500 · Nifty Total Market

₹1,677.20-2.34% today
Market cap
₹27,778 Cr
P/E
85.51
ROE
26.96%
PEG
0.55
Price to sales
13.22
Debt to equity
0.35
52W high / low
₹1,861 / ₹615
Sales growth (5Y)
41.00%
EBITDA margin
23.81%
Net profit margin
14.06%
Promoter holding
51.25%
Sales (last year)
₹2,100 Cr

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]

Guidance scorecard · Q2 FY27 call

What Rubicon Research's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#68of 87 in
Pharmaceuticals & Biotechnology

RevenueQ2 FY27 call

10–20%
  • Sequential USD revenue growth was 5% in the recent quarter with strong visibility for upcoming quarters.
  • Focus on steady ramp-up of new products ensuring stable margins; specialty/differentiated products contributing significantly to gross profit.
  • Revenue growth is expected through commercialization of products and regulatory approvals, with licensing processes recently updated.
  • R&D productivity has improved significantly, with a 5.9x incremental revenue growth against R&D spend expected by FY 2027, indicating strong revenue growth visibility for FY 2029, FY 2030, and beyond.
  • Three pre-revenue manufacturing facilities (Indore, CSN, New Jersey) expected to start contributing by FY 2028 onwards, providing further growth potential.

2 more points from Rubicon Research's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Rubicon Research said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Capex driven by acquisition of Arinna Lifesciences and New Jersey-based manufacturing facility.
  • Fixed asset base grew by INR 85 crores for New Jersey facility; cash payout was INR 29 crores; INR 55 crores non-cash right-of-use.
  • Capital employed includes nearly INR 400 crores (25% of total capital) in pre-revenue assets such as Pithampur, Chhatrapati Sambhajinagar (Aurangabad), New Jersey facility, and Arinna Lifesciences.

2 more points from Rubicon Research's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Rubicon Research said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

Ask what Rubicon Research said on the order book →

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Rubicon Research latest results (Sep 2026)

Revenue

₹576 Cr

+40% YoY

Net profit

₹90 Cr

+67% YoY

Operating margin

25%

EPS

₹5.47

What management said on the call →

Rubicon Research shareholding (Sep 2026)

Promoters

51.25%

−8.51 pp QoQ

FIIs

9.01%

+1.49 pp QoQ

DIIs

15.73%

+6.30 pp QoQ

Public

24.03%

+0.74 pp QoQ

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Rubicon Research announcements

All announcements →

Financials of Rubicon Research

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Rubicon Research

Shareholding breakup across reporting periods.

Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +59.99%59.86%59.76%51.25%
FIIs +7.99%7.54%7.52%9.01%
DIIs +9.45%10.02%9.43%15.73%
Public +22.57%22.57%23.29%24.03%
No. of Shareholders31,91433,73843,25438,018

Financials of Rubicon Research

Quarterly Results

Quarter-by-quarter operating performance

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +296313358352412476514534576
YoY Sales growth+39%+52%+43%+52%+40%
Expenses +234244286273318367395405432
Operating Profit6270727994108119129144
OPM %21%22%20%22%23%23%23%24%25%
Other Income +300114362
Interest781211111010911
Depreciation8910101212121518
Profit before tax49535160729199110117
Tax %30%28%29%27%25%20%22%23%23%
Net Profit +343836435473778590
EPS in Rs2.272.502.352.813.494.424.655.135.47

Financials of Rubicon Research

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +2633153143948541,2841,7542,100
Sales growth+20%-0%+26%+117%+50%+37%+46%
Expenses +1822233533756991,0201,3541,600
Operating Profit8192-3918155264400500
OPM %31%29%-12%4.7%18%21%23%24%
Other Income +18101725184814
Interest69101931374241
Depreciation1829343639374557
Profit before tax7463-66-11103195321417
Tax %33%51%2%53%12%31%23%
Net Profit +4931-67-1791134247325
EPS in Rs3.252.02-4.42-1.115.988.7214.9519.67
Dividend Payout %2%2%-0%-2%0%0%10%

Financials of Rubicon Research

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital555515151717
Reserves3353693002813705261,2721,400
Borrowings +3093175320425418311501
Other Liabilities +607179144300493727843
Total Liabilities4305385607501,1091,4512,3272,761
Fixed Assets +157188193199307327532803
CWIP263251074190
Investments191400002729
Other Assets +2523303645267931,1181,7281,839
Total Assets4305385607501,1091,4512,3272,761

Financials of Rubicon Research

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +562-63-7521159205
Cash from Investing Activity +-84-46-46-32-68-65-407
Cash from Financing Activity +80526312344-40283
Net Cash Flow167-4516-45481
Free Cash Flow-54-10-117-119-3591-24
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit40%104%138%-394%25%75%78%

Financials of Rubicon Research

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days19415816220912992106
Inventory Days360508502609428574550
Days Payable183271320353252263285
Cash Conversion Cycle371395345465305403371
Working Capital Days183149107755746104
ROCE %17%-12%1%19%26%28%

Guidance history

How Rubicon Research's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →10–20%FlatPlanned——
Q1 FY27 call →20–40%FlatPlanned——
Q4 FY26 call →20–40%FlatPlannedPlanned—
Q3 FY26 call →20–40%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

90out of 100

Momentum score · price trend

90 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,938 stocks
Last 12 months+156.3%97%
Last 6 months+74.5%94%
Last 3 months+3.6%68%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,938 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Rubicon Research: 0.4 × 97 + 0.4 × 94 + 0.2 × 68 = 90.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Rubicon Research: frequently asked questions

What is Rubicon Research share price today?

Rubicon Research last traded at ₹1,677.2, with a market capitalisation of ₹27,778 Cr and a P/E ratio of 85.5.

What were Rubicon Research's latest quarterly results?

For the quarter ended Sep 2026, Rubicon Research reported revenue of ₹576 Cr (+40% year on year) and net profit of ₹90 Cr, with an operating margin of 25%.

Is Rubicon Research's profit growing?

Net profit was ₹90 Cr in Sep 2026 against ₹54 Cr in Sep 2025, a change of +67%.

What is Rubicon Research's EPS?

Rubicon Research's earnings per share for the quarter ended Sep 2026 was ₹5.47.

What is the promoter holding in Rubicon Research?

Promoters held 51.25% of Rubicon Research in Sep 2026 (−8.51 pp versus Jun 2026).

How much do FIIs and DIIs hold in Rubicon Research?

In Sep 2026, foreign institutional investors held 9.01% and domestic institutions (including mutual funds) held 15.73% of Rubicon Research.

What is Rubicon Research's ROE and ROCE?

Rubicon Research's return on equity is 27% and its return on capital employed is 28.4%.

Does Rubicon Research pay a dividend?

Yes. Rubicon Research's dividend yield is 0.09% at the current price. The full payout history is on the Rubicon Research dividends page.

Which sector does Rubicon Research belong to?

Rubicon Research is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Rubicon Research's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Rubicon Research's management.

How does Arthneeti AI analyse Rubicon Research?

Arthneeti reads Rubicon Research's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Others in Pharmaceuticals & Biotechnology this season

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.